Cullinan Therapeutics Delays Early-Stage Data Release for Arthritis Drug
Shares of Cullinan Therapeutics (CGTX) declined on Thursday after the company announced a delay in releasing early-stage trial data for its experimental arthritis drug, CLN-978. The biotech firm now expects to provide multi-dose regimen results later than previously anticipated. The setback comes as investors had been closely watching Cullinan's progress with CLN-978, which is being developed as a bispecific T cell engager for the treatment of rheumatoid arthritis. Delays in clinical data can raise concerns about development timelines and investor confidence. Cullinan operates from Cambridge, Massachusetts, and has been working on innovative therapies targeting autoimmune diseases.
